Abbott Laboratories (ABT) Long-Term Debt Issuances (2010 - 2026)

Abbott Laboratories has reported Long-Term Debt Issuances for 10 years, with the latest figure at -$33.0 million in Q2 2026.

• Quarterly Long-Term Debt Issuances fell 1750.0% year-over-year to -$33.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $19.8 billion (up 396480.0% YoY) and the FY2025 annual result came in at $5.0 million, down 97.76% from the prior year.
• Long-Term Debt Issuances retreated to -$33.0 million in Q2 2026 per ABT's latest filing, from $19.9 billion in the prior quarter.
• Over five years, Long-Term Debt Issuances peaked at $19.9 billion in Q1 2026 and troughed at -$33.0 million in Q2 2026.
• A 5-year average of $2.0 billion and a median of $1.0 million in 2022 frame the typical range for Long-Term Debt Issuances.
• The widest YoY moves for Long-Term Debt Issuances: up 1985900.0% in 2026, down 1750.0% in 2026.
• Over 5 years, Long-Term Debt Issuances stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then surged by 100.0% to $2.0 million in 2025, then plunged by 1750.0% to -$33.0 million in 2026.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered -$33.0 million, $19.9 billion, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.